The funds are expected to more than double the company's current manufacturing capacity and support biopharma customers as they ramp up to meet short-term demands related to COVID-19, as well as long-term efforts to develop new vaccines and biologics for other conditions.

Thermo Fisher's single-use technologies business is expanding capacity at sites in Logan, UT, Millersburg, PA, Cramlington, U.K., Singapore, and Suzhou, China. Additional investment at its site in Santa Clara, CA, will expand bioprocessing equipment and automation capacity.

Also, the company will expand its POROS resin manufacturing site in Bedford, MA and open a new 85,000-sq-ft manufacturing facility in Chelmsford, MA. Finally, it will expand production of Gibco cell culture media, supplements, and processing liquids by expanding capacity at its sites in Grand Island, NY, Miami, and Inchinnan, Scotland.

Thermo Fisher acquires cell-sorting technology from Propel Labs
Thermo Fisher Scientific acquired cell-sorting technology assets from Propel Labs, a wholly owned subsidiary of SIDIS. Under the terms of the agreement,...

Thermo Fisher launches new electron microscope
Thermo Fisher Scientific has unveiled its new Helios 5 PXL Wafer DualBeam, a plasma-focused ion beam scanning electron microscope. The microscope can...

Thermo Fisher Scientific releases nano and capillary emitters
Thermo Fisher Scientific has released a MAbPac reversed-phase capillary high-performance liquid chromatography column, as well as new nano and capillary...

Thermo Fisher inks CAR T deal with JW Therapeutics
Thermo Fisher has signed a marketing agreement with Chinese firm JW Therapeutics to supply that company with its Gibco CTS Dynabeads CD3/CD28. The agreement...

Thermo Fisher introduces cell therapy workflow media
Thermo Fisher Scientific has launched a new medium of the first human T lymphocytes (T cells) specifically designed for allogeneic cell therapy workflows.